AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market
Executive Summary
AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.
You may also be interested in...
AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer
Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.
How To Save A Drug: Iressa’s Return Relied On Consistency Across Totality Of Evidence
Drug Review Profile of the second life of AstraZeneca’s Iressa shows how FDA adapts to imperfect but improving information without putting undue burden on sponsors – and how the agency recently applied a similar iterative approach to another EGFR inhibitor, Astellas and Genentech’s Tarceva.
Boehringer’s Oncology Strategy: Build From Niche Lung Cancer Base
With Gilotrif sales building over time, private Boehringer Ingelheim turns its focus to broad development program for its third-generation EGFR inhibitor olmutinib, with ambition to become a leader in lung cancer.